Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

24/09/2015 Rankings: UAB, UB and UPF Confirm the Quality of the Universities of Barcelona 18/09/2015 With Stradivarius, Design and Fashion Arrive in the Barcelona Synchrotron Park 09/09/2015 The ALBA Synchrotron in the Development of Future Computers 03/09/2015 Travelling to Mars Is In Progress Near the Barcelona Synchrotron Park 09/08/2015 A Synchrotron Is Also Good at Paleontology, Art or History 29/07/2015 Barcelona, an Attractive City for Foreign Direct Investments
30 31 32 33 34 35 36 37 38 39 40